• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Guided Therapeutics Inc (OP: GTHP )

    0.1390 UNCHANGED
    Streaming Delayed Price Updated: 12:25 PM EDT, Jul 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 17
    Open 0.1390
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 0.1390
    Today's Range 0.1390 - 0.1390
    52wk Range 0.0640 - 0.3000
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Guided Therapeutics’ Announces Data from Chinese NMPA Clinical Study Signed Off by All Four Clinical Sites With Better Than Expected Results
    From Guided Therapeutics, Inc.
    Via Business Wire
    Leading Cervical Cancer Doctors Support Approval of LuViva in China Based on Preliminary Review of Clinical Trial Results
    From Guided Therapeutics, Inc.
    Via Business Wire

    Performance

    YTD
    -4.27%
    -4.27%
    1 Month
    +15.83%
    +15.83%
    3 Month
    +59.22%
    +59.22%
    6 Month
    -4.14%
    -4.14%
    1 Year
    -22.78%
    -22.78%

    More News

    Read More
    Guided Therapeutics Announces Completion of Clinical Study for Chinese Regulatory Approval
    From Guided Therapeutics, Inc.
    Via Business Wire
    Guided Therapeutics Provides Update on Start of Clinical Trial for US FDA Approval
    From Guided Therapeutics, Inc.
    Via Business Wire
    Guided Therapeutics Announces New Agreement and Purchase Orders from Shandong Yaohua Medical Instrument Corporation
    From Guided Therapeutics, Inc.
    Via Business Wire
    Guided Therapeutics Signs Agreement to Begin Clinical Trial for US FDA Approval
    From Guided Therapeutics, Inc.
    Via Business Wire
    Guided Therapeutics Provides Update of Significant Progress in Chinese Clinical Study for Marketing Approval of the LuViva Advanced Cervical Scan
    From Guided Therapeutics, Inc.
    Via Business Wire
    Guided Therapeutics Closes $3.3 Million Bridge Financing
    From Guided Therapeutics, Inc.
    Via Business Wire
    Guided Therapeutics Receives Institutional Review Board Approval to Start Clinical Study for FDA Approval of the LuViva® Advanced Cervical Scan
    From Guided Therapeutics, Inc.
    Via Business Wire
    Guided Therapeutics Announces Testing Completion of First 150 Patients in Chinese Clinical Study and Receives Milestone Payment of $177,740
    From Guided Therapeutics, Inc.
    Via Business Wire
    Guided Therapeutics Announces Start of Chinese Clinical Trial for Approval to Market and Sell LuViva in China
    From Guided Therapeutics, Inc.
    Via Business Wire
    Guided Therapeutics Ships LuViva Devices to China for Start of Clinical Trial; Receives Additional $100,000 Payment
    From Guided Therapeutics, Inc.
    Via Business Wire
    Guided Therapeutics Receives Notification of Successful Clinical Trial Regulatory Review and $133,000 Payment from China
    From Guided Therapeutics, Inc.
    Via Business Wire
    New European Published Study Shows LuViva Detects 20% More Precancerous and Cancerous Cervical Disease than HPV Test
    From Guided Therapeutics, Inc.
    Via Business Wire
    Guided Therapeutics Receives News from Chinese State Food and Drug Administration that LuViva Meets Product Technical Requirements
    From Guided Therapeutics, Inc.
    Via Business Wire
    Guided Therapeutics Replaces Convertible Note Facility and Significantly Reduces Dilution
    From Guided Therapeutics, Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.